Viking Finalizes $225M Convertible Notes at $50.75 Conversion Price, Upsizing Concurrent Raise to $500M
VKTX sits 49% above its 52-week low of $24.78 on elevated volume (8.5× avg).
Summary
Viking Therapeutics finalized a $225 million convertible notes offering at a $50.75 conversion price, completing a $500 million concurrent capital raise with the common stock tranche. Proceeds fund the VK2735 obesity program through Phase 3 development.
Key Events · Financing and Capital Events · VKTX
-
Convertible Notes Upsized to $225M
The notes tranche increased from $200M to $225M principal (plus $33.75M over-allotment option), with a 2.00% coupon due 2032.
-
Conversion Price Set at $50.75
An initial conversion rate of 19.7044 shares per $1,000 principal represents a 24% premium to the $40.85 last reported sale price on September 22, 2026.
-
Total Raise Reaches $500M
Combined with the concurrent 7.86M-share common stock offering at $35.00, total gross proceeds reach $500M, up from the original $400M plan.
-
Net Proceeds Fund VK2735 Program
Approximately $476M in combined net proceeds will fund Phase 3 VANQUISH trials, oral dosing studies starting Q4 2026, and VK3019 development.
Analysis · VKTX · Life Sciences
The terms of Viking Therapeutics' convertible senior notes offering are now final, with the notes tranche upsized to $225 million from the previously announced $200 million. The notes carry a 2.00% coupon and convert at approximately $50.75 per share — a 24% premium to the $40.85 last reported sale price on September 22, 2026. Combined with the concurrent common stock offering of 7.86 million shares at $35.00, the total raise reaches $500 million, up from the original $400 million plan. The conversion premium and upsized demand reflect institutional confidence in the VK2735 obesity program following the positive Phase 2 maintenance data announced September 22. Net proceeds of approximately $476 million across both tranches extend the cash runway for Phase 3 VANQUISH trials and oral dosing studies expected to begin in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $36.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $24.78 to $43.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.